{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T01:02:54Z","timestamp":1791248574987,"version":"4.1.0"},"reference-count":84,"publisher":"MDPI AG","issue":"3","license":[{"start":{"date-parts":[[2022,1,21]],"date-time":"2022-01-21T00:00:00Z","timestamp":1642723200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cells"],"abstract":"<jats:p>Non-muscle-invasive bladder cancer (NMIBC) is characterized by a high rate of cure, but also by a non-negligible probability of recurrence and risk progression to muscle-invasive disease. NMIBC management requires a proper local resection and staging, followed by a risk-based treatment with intravesical agents. For many years, the current gold standard treatment for patients with intermediate or high-risk disease is transurethral resection of the bladder (TURB) followed by intravesical bacillus Calmette\u2013Gu\u00e9rin (BCG) instillations. Unfortunately, in about half of high-risk patients, intravesical BCG treatment fails and NMIBC persists or recurs early. While radical cystectomy remains the gold standard for these patients, new therapeutic targets are being individuated and studied. Radical cystectomy in fact can provide an excellent long-term disease control, but can deeply interfere with quality of life. In particular, the enhanced immune checkpoints expression shown in BCG-unresponsive patients and the activity of immune checkpoints inhibitors (ICIs) in advanced bladder cancer provided the rationale for testing ICIs in NMIBC. Recently, pembrolizumab has shown promising activity in BCG-unresponsive NMIBC patients, obtaining FDA approval. Meanwhile multiple novel drugs with alternative mechanisms of action have proven to be safe and effective in NMIBC treatment and others are under investigation. The aim of this review is to analyse and describe the clinical activity of new emerging drugs in BCG-unresponsive NMIBC focusing on immunotherapy results.<\/jats:p>","DOI":"10.3390\/cells11030357","type":"journal-article","created":{"date-parts":[[2022,1,21]],"date-time":"2022-01-21T08:37:18Z","timestamp":1642754238000},"page":"357","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":38,"title":["New Perspectives in the Medical Treatment of Non-Muscle-Invasive Bladder Cancer: Immune Checkpoint Inhibitors and Beyond"],"prefix":"10.3390","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7101-2100","authenticated-orcid":false,"given":"Alessandro","family":"Audisio","sequence":"first","affiliation":[{"name":"Department of Oncology, University of Turin, San Luigi Gonzaga Hospital, Orbassano, 10093 Turin, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Consuelo","family":"Buttigliero","sequence":"additional","affiliation":[{"name":"Department of Oncology, University of Turin, San Luigi Gonzaga Hospital, Orbassano, 10093 Turin, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco Donatello","family":"Delcuratolo","sequence":"additional","affiliation":[{"name":"Department of Oncology, University of Turin, San Luigi Gonzaga Hospital, Orbassano, 10093 Turin, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Parlagreco","sequence":"additional","affiliation":[{"name":"Department of Oncology, University of Turin, San Luigi Gonzaga Hospital, Orbassano, 10093 Turin, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Audisio","sequence":"additional","affiliation":[{"name":"Department of Oncology, University of Turin, San Luigi Gonzaga Hospital, Orbassano, 10093 Turin, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0548-2611","authenticated-orcid":false,"given":"Antonio","family":"Ungaro","sequence":"additional","affiliation":[{"name":"Department of Oncology, University of Turin, San Luigi Gonzaga Hospital, Orbassano, 10093 Turin, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosario Francesco","family":"Di Stefano","sequence":"additional","affiliation":[{"name":"Department of Oncology, University of Turin, San Luigi Gonzaga Hospital, Orbassano, 10093 Turin, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lavinia","family":"Di Prima","sequence":"additional","affiliation":[{"name":"Department of Oncology, University of Turin, San Luigi Gonzaga Hospital, Orbassano, 10093 Turin, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3111-7888","authenticated-orcid":false,"given":"Fabio","family":"Turco","sequence":"additional","affiliation":[{"name":"Department of Oncology, University of Turin, San Luigi Gonzaga Hospital, Orbassano, 10093 Turin, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcello","family":"Tucci","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Cardinal Massaia Hospital, 14100 Asti, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2022,1,21]]},"reference":[{"key":"ref_1","unstructured":"Globocan IARC Cancer Today (2021, December 31). Bladder Cancer Fact Sheet. Available online: https:\/\/gco.iarc.fr\/today\/data\/factsheets\/cancers\/30-Bladder-fact-sheet.pdf."},{"key":"ref_2","first-page":"1","article-title":"Non-muscle-invasive Bladder Cancer (TaT1 and CIS) EAU Guidelines","volume":"31","author":"Gontero","year":"2019","journal-title":"Eur. Urol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"2796","DOI":"10.1016\/S0140-6736(16)30512-8","article-title":"Bladder cancer","volume":"388","author":"Kamat","year":"2016","journal-title":"Lancet"},{"key":"ref_4","doi-asserted-by":"crossref","unstructured":"Powles, T., Bellmunt, J., Comperat, E., De Santis, M., Huddart, R., Loriot, Y., Necchi, A., Valderrama, B.P., Ravaud, A., and Shariat, S.F. (2021). Bladder cancer: ESMO clinical practice guideline for diagnosis, treatment and follow-up. Ann. Oncol.","DOI":"10.1016\/j.annonc.2021.11.012"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.eururo.2021.08.010","article-title":"European Association of Urology Guidelines on Non\u2013muscle-invasive Bladder Cancer (Ta, T1, and Carcinoma in Situ)","volume":"81","author":"Babjuk","year":"2021","journal-title":"Eur. Urol."},{"key":"ref_6","unstructured":"National Comprehensive Cancer Network (2021, October 31). Bladder Cancer. NCCN Clin Pract Guidel Oncol. Available online: https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/bladder.pdf."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1016\/j.juro.2016.06.049","article-title":"Diagnosis and Treatment of Non-Muscle Invasive Bladder Cancer: AUA\/SUO Guideline","volume":"196","author":"Chang","year":"2016","journal-title":"J. Urol."},{"key":"ref_8","first-page":"499","article-title":"Carcinoma in situ","volume":"19","author":"Lamm","year":"1992","journal-title":"Urol. Clin. N. Am."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1097\/01.ju.0000162059.64886.1c","article-title":"Bacillus calmette-guerin versus chemotherapy for the intravesical treatment of patients with carcinoma in situ of the bladder: A meta-analysis of the published results of randomized clinical trials","volume":"174","author":"Sylvester","year":"2005","journal-title":"J. Urol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/j.juro.2013.08.022","article-title":"The effect of restaging transurethral resection on recurrence and progression rates in patients with nonmuscle invasive bladder cancer treated with intravesical bacillus Calmette-Gu\u00e9rin","volume":"191","author":"Sfakianos","year":"2014","journal-title":"J. Urol."},{"key":"ref_11","first-page":"275","article-title":"Postoperative nomogram predicting risk of recurrence after radical cystectomy for bladder cancer: International Bladder Cancer Nomogram Consortium, Bochner BH, Kattan MW, Vora KC, Department of Urology, Memorial Sloan-Kettering Cancer Center, Kimmel Center for Prostate and Urologic Tumors, New York, NY","volume":"25","author":"See","year":"2007","journal-title":"Urol. Oncol. Semin. Orig. Investig."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.eururo.2015.06.045","article-title":"EORTC Nomograms and Risk Groups for Predicting Recurrence, Progression, and Disease-specific and Overall Survival in Non-Muscle-invasive Stage Ta-T1 Urothelial Bladder Cancer Patients Treated with 1-3 Years of Maintenance Bacillus Calmette-Gu\u00e9rin","volume":"69","author":"Cambier","year":"2016","journal-title":"Eur. Urol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1016\/S0022-5347(05)67799-3","article-title":"Efficacy and safety of valrubicin for the treatment of Bacillus Calmette-Guerin refractory carcinoma in situ of the bladder. The Valrubicin Study Group","volume":"163","author":"Steinberg","year":"2000","journal-title":"J. Urol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"2729","DOI":"10.1200\/JCO.2005.05.2720","article-title":"Phase II trial of intravesical gemcitabine in bacille Calmette-Gu\u00e9rin-refractory transitional cell carcinoma of the bladder","volume":"24","author":"Dalbagni","year":"2006","journal-title":"J. Clin. Oncol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1016\/j.juro.2012.10.068","article-title":"Long-term survival outcomes with intravesical docetaxel for recurrent nonmuscle invasive bladder cancer after previous bacillus Calmette-Gu\u00e9rin therapy","volume":"189","author":"Barlow","year":"2013","journal-title":"J. Urol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1633","DOI":"10.1016\/j.juro.2014.06.084","article-title":"Phase II trial of intravesical nanoparticle albumin bound paclitaxel for the treatment of nonmuscle invasive urothelial carcinoma of the bladder after bacillus Calmette-Gu\u00e9rin treatment failure","volume":"192","author":"McKiernan","year":"2014","journal-title":"J. Urol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"65","DOI":"10.3233\/BLC-150008","article-title":"Sequential Intravesical Gemcitabine and Docetaxel for the Salvage Treatment of Non-Muscle Invasive Bladder Cancer","volume":"1","author":"Steinberg","year":"2015","journal-title":"Bladder Cancer"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"e15","DOI":"10.1016\/j.urolonc.2013.01.009","article-title":"Multi-institutional analysis of sequential intravesical gemcitabine and mitomycin C chemotherapy for non-muscle invasive bladder cancer","volume":"32","author":"Lightfoot","year":"2014","journal-title":"Urol. Oncol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1016\/S1470-2045(21)00147-9","article-title":"Pembrolizumab monotherapy for the treatment of high-risk non-muscle-invasive bladder cancer unresponsive to BCG (KEYNOTE-057): An open-label, single-arm, multicentre, phase 2 study","volume":"22","author":"Balar","year":"2021","journal-title":"Lancet Oncol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"4541","DOI":"10.1200\/JCO.2021.39.15_suppl.4541","article-title":"Phase II trial of atezolizumab in BCG-unresponsive non-muscle invasive bladder cancer: SWOG S1605 (NCT #02844816)","volume":"39","author":"Black","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/S1470-2045(20)30540-4","article-title":"Intravesical nadofaragene firadenovec gene therapy for BCG-unresponsive non-muscle-invasive bladder cancer: A single-arm, open-label, repeat-dose clinical trial","volume":"22","author":"Boorjian","year":"2021","journal-title":"Lancet Oncol."},{"key":"ref_22","first-page":"e72","article-title":"PD03-02 Phase 3 results of Vicineum in BCG-unresponsive Non-Muscle Invasive Bladder Cancer","volume":"203","author":"Shore","year":"2020","journal-title":"J. Urol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/S0022-5347(17)58737-6","article-title":"Intracavitary Bacillus Calmette-Guerin in the treatment of superficial bladder tumors","volume":"116","author":"Morales","year":"1976","journal-title":"J. Urol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1111\/apm.13011","article-title":"Bacillus Calmette\u2013Gu\u00e9rin immunotherapy for bladder cancer: A review of immunological aspects, clinical effects and BCG infections","volume":"128","author":"Larsen","year":"2020","journal-title":"Apmis"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1038\/mi.2013.72","article-title":"From infection to immunotherapy: Host immune responses to bacteria at the bladder mucosa","volume":"6","author":"Ingersoll","year":"2013","journal-title":"Mucosal Immunol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1007\/BF00299721","article-title":"Morphological aspects of the interaction of Bacillus Calmette-Gu\u00e9rin with urothelial bladder cells in vivo and in vitro: Relevance for antitumor activity?","volume":"20","author":"Teppema","year":"1992","journal-title":"Urol. Res."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1571","DOI":"10.1016\/j.juro.2008.11.124","article-title":"Molecular analyte profiling of the early events and tissue conditioning following intravesical bacillus calmette-guerin therapy in patients with superficial bladder cancer","volume":"181","author":"Bisiaux","year":"2009","journal-title":"J. Urol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"3386","DOI":"10.1158\/0008-5472.CAN-04-0374","article-title":"Tumor necrosis factor-related apoptosis-inducing ligand: A novel mechanism for Bacillus Calmette-Gu\u00e9rin-induced antitumor activity","volume":"64","author":"Ludwig","year":"2004","journal-title":"Cancer Res."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1016\/S0022-5347(17)45922-2","article-title":"Histological parameters and pitfalls in the interpretation of bladder biopsies in bacillus Calmette-Guerin treatment of superficial bladder cancer","volume":"135","author":"Lage","year":"1986","journal-title":"J. Urol."},{"key":"ref_30","first-page":"611","article-title":"Novel insights into the mechanism of action of intravesical immunomodulators","volume":"19","author":"Mitropoulos","year":"2005","journal-title":"In Vivo"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1016\/S0022-5347(17)41343-7","article-title":"Class I and class II HLA antigen expression by transitional cell carcinoma of the bladder: Correlation with T-cell infiltration and BCG treatment","volume":"141","author":"Stefanini","year":"1989","journal-title":"J. Urol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1046\/j.1442-2042.2002.00415.x","article-title":"Surface antigen expression on bladder tumor cells induced by bacillus Calmette-Gu\u00e9rin (BCG): A role of BCG internalization into tumor cells","volume":"9","author":"Ikeda","year":"2002","journal-title":"Int. J. Urol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.4161\/onci.20640","article-title":"Blocking IL-10 enhances bacillus Calmette-Gu\u00e9rin induced T helper Type 1 immune responses and anti-bladder cancer immunity","volume":"1","author":"Luo","year":"2012","journal-title":"Oncoimmunology"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1038\/s41585-018-0055-4","article-title":"Mechanisms of BCG immunotherapy and its outlook for bladder cancer","volume":"15","author":"Pettenati","year":"2018","journal-title":"Nat. Rev. Urol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1038\/nrc3239","article-title":"The blockade of immune checkpoints in cancer immunotherapy","volume":"12","author":"Pardoll","year":"2012","journal-title":"Nat. Rev. Cancer"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1038\/nrc.2016.36","article-title":"Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy","volume":"16","author":"Topalian","year":"2016","journal-title":"Nat. Rev. Cancer"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1158\/1078-0432.CCR-19-1920","article-title":"Adaptive immune resistance to intravesical BCG in non\u2013muscle invasive bladder cancer: Implications for prospective BCG-unresponsive trials","volume":"26","author":"Kates","year":"2020","journal-title":"Clin. Cancer Res."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1007\/s00428-020-02755-2","article-title":"PD-L1 expression in bladder primary in situ urothelial carcinoma: Evaluation in BCG-unresponsive patients and BCG responders","volume":"477","author":"Pierconti","year":"2020","journal-title":"Virchows Arch."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"34066","DOI":"10.18632\/oncotarget.26122","article-title":"Enhanced expression of PD-L1 in non-muscle-invasive bladder cancer after treatment with Bacillus Calmette-Guerin","volume":"9","author":"Hashizume","year":"2018","journal-title":"Oncotarget"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"2484","DOI":"10.1245\/s10434-018-6498-2","article-title":"Clinical Role of Programmed Cell Death-1 Expression in Patients with Non-muscle-invasive Bladder Cancer Recurring After Initial Bacillus Calmette\u2013Gu\u00e9rin Therapy","volume":"25","author":"Fukumoto","year":"2018","journal-title":"Ann. Surg. Oncol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1016\/j.eururo.2018.06.045","article-title":"Conventional and PD-L1-expressing Regulatory T Cells are Enriched During BCG Therapy and may Limit its Efficacy","volume":"74","author":"Chevalier","year":"2018","journal-title":"Eur. Urol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"3655","DOI":"10.1038\/s41598-019-40145-0","article-title":"Bacillus Calmette-Gu\u00e9rin Induces PD-L1 Expression on Antigen-Presenting Cells via Autocrine and Paracrine Interleukin-STAT3 Circuits","volume":"9","author":"Copland","year":"2019","journal-title":"Sci. Rep."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1038\/nature12477","article-title":"Signatures of mutational processes in human cancer","volume":"500","author":"Alexandrov","year":"2013","journal-title":"Nature"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1038\/s41588-018-0312-8","article-title":"Tumor mutational load predicts survival after immunotherapy across multiple cancer types","volume":"51","author":"Samstein","year":"2019","journal-title":"Nat. Genet."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1056\/NEJMoa1613683","article-title":"Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma","volume":"376","author":"Bellmunt","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_46","doi-asserted-by":"crossref","unstructured":"Roviello, G., Catalano, M., Santi, R., Palmieri, V.E., Vannini, G., Galli, I.C., Buttitta, E., Villari, D., Rossi, V., and Nesi, G. (2021). Immune checkpoint inhibitors in urothelial bladder cancer: State of the art and future perspectives. Cancers, 13.","DOI":"10.3390\/cancers13174411"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.1056\/NEJMoa2002788","article-title":"Avelumab Maintenance Therapy for Advanced or Metastatic Urothelial Carcinoma","volume":"383","author":"Powles","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"2102","DOI":"10.1056\/NEJMoa2034442","article-title":"Adjuvant Nivolumab versus Placebo in Muscle-Invasive Urothelial Carcinoma","volume":"384","author":"Bajorin","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.1016\/S0140-6736(16)00561-4","article-title":"Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: A single-arm, multicentre, phase 2 trial","volume":"387","author":"Rosenberg","year":"2016","journal-title":"Lancet"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"5022","DOI":"10.1200\/JCO.2020.38.15_suppl.5022","article-title":"Phase II trial of atezolizumab in BCG-unresponsive non-muscle invasive bladder cancer: SWOG S1605 (NCT #02844816)","volume":"38","author":"Black","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"ref_51","first-page":"e1177","article-title":"LBA02-04 Novel weekly immunotherapy dosing with avelumab tolerated during Bacillus Calmette-Guerin induction therapy: Initial results of the ABC trial","volume":"206","author":"Michael","year":"2021","journal-title":"J. Urol."},{"key":"ref_52","unstructured":"(2021, November 23). Definition of Multipeptide Vaccine S-588210\u2014NCI Drug Dictionary\u2014National Cancer Institute, Available online: https:\/\/www.cancer.gov\/publications\/dictionaries\/cancer-drug\/def\/multipeptide-vaccine-s-588210."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"2041","DOI":"10.1007\/s00345-018-2553-7","article-title":"The development of interferon-based gene therapy for BCG unresponsive bladder cancer: From bench to bedside","volume":"37","author":"Duplisea","year":"2019","journal-title":"World J. Urol."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1046\/j.1464-410X.2002.02734.x","article-title":"A randomized comparative dose-ranging study of interferon-alpha and mitomycin-C as an internal control in primary or recurrent superficial transitional cell carcinoma of the bladder","volume":"89","year":"2002","journal-title":"BJU Int."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1016\/j.urology.2005.02.015","article-title":"Sustained intravesical interferon protein exposure is achieved using an adenoviral-mediated gene delivery system: A study in rats evaluating dosing regimens","volume":"66","author":"Connor","year":"2005","journal-title":"Urology"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1016\/j.juro.2013.03.030","article-title":"Phase I trial of intravesical recombinant adenovirus mediated interferon-\u03b12b formulated in Syn3 for Bacillus Calmette-Gu\u00e9rin failures in nonmuscle invasive bladder cancer","volume":"190","author":"Dinney","year":"2013","journal-title":"J. Urol."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"3410","DOI":"10.1200\/JCO.2017.72.3064","article-title":"Intravesical rAd-IFN\u03b1\/Syn3 for Patients With High-Grade, Bacillus Calmette-Guerin-Refractory or Relapsed Non-Muscle-Invasive Bladder Cancer: A Phase II Randomized Study","volume":"35","author":"Shore","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"e296","DOI":"10.1097\/JU.0000000000002001.01","article-title":"MP16-01 Efficacy of nadofaragene firadenovec for patients with carcinoma in situ (CIS), BCG-unresponsive non-muscle invasive bladder cancer (NMIBC): Longer-term follow-up from the phase III trial","volume":"206","author":"Schuckman","year":"2021","journal-title":"J. Urol."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"e296","DOI":"10.1097\/JU.0000000000002001.02","article-title":"MP16-02 Phase III trial of intravescical nadofaragene firadenovec in patients with high-grade BCG-unresponsive, non-muscle invasive bladder cancer: Two-year follow up in the Ta\/T1 cohort","volume":"206","author":"Lotan","year":"2021","journal-title":"J. Urol."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1158\/1078-0432.CCR-05-1059","article-title":"CG0070, a Conditionally Replicating Granulocyte Macrophage Colony-Stimulating Factor\u2013Armed Oncolytic Adenovirus for the Treatment of Bladder Cancer","volume":"12","author":"Ramesh","year":"2006","journal-title":"Clin. Cancer Res."},{"key":"ref_61","first-page":"440","article-title":"An open label, single-arm, phase II multicenter study of the safety and efficacy of CG0070 oncolytic vector regimen in patients with BCG-unresponsive non\u2013muscle-invasive bladder cancer: Interim results","volume":"36","author":"Packiam","year":"2018","journal-title":"Urol. Oncol. Semin. Orig. Investig."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1080\/13543776.2018.1441290","article-title":"A patent review of IDO1 inhibitors for cancer","volume":"28","author":"Cheong","year":"2018","journal-title":"Expert Opin. Ther. Pat."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.ucl.2019.09.013","article-title":"Role of Indoleamine-2,3-Dioxygenase Inhibitors in Salvage Therapy for Non-Muscle Invasive Bladder Cancer","volume":"47","author":"Chu","year":"2020","journal-title":"Urol. Clin. N. Am."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1038\/nri1901","article-title":"The biology of interleukin-2 and interleukin-15: Implications for cancer therapy and vaccine design","volume":"6","author":"Waldmann","year":"2006","journal-title":"Nat. Rev. Immunol."},{"key":"ref_65","doi-asserted-by":"crossref","unstructured":"Gomes-Giacoia, E., Miyake, M., Goodison, S., Sriharan, A., Zhang, G., You, L., Egan, J.O., Rhode, P.R., Parker, A.S., and Chai, K.X. (2014). Intravesical ALT-803 and BCG treatment reduces tumor burden in a carcinogen induced bladder cancer rat model; a role for cytokine production and NK cell expansion. PLoS ONE, 9.","DOI":"10.1371\/journal.pone.0096705"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"1912885","DOI":"10.1080\/2162402X.2021.1912885","article-title":"Safety, Tolerability, and Long-Term Clinical Outcomes of an IL-15 analogue (N-803) Admixed with Bacillus Calmette-Gu\u00e9rin (BCG) for the Treatment of Bladder Cancer","volume":"10","author":"Rosser","year":"2021","journal-title":"Oncoimmunology"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"4561","DOI":"10.1200\/JCO.2019.37.15_suppl.4561","article-title":"Preliminary phase 2 clinical results of IL-15R\u03b1Fc superagonist N-803 with BCG in BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) patients","volume":"37","author":"Chamie","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"e12818","DOI":"10.1111\/sji.12818","article-title":"Toll-like receptors: The role in bladder cancer development, progression and immunotherapy","volume":"90","author":"Nowroozi","year":"2019","journal-title":"Scand. J. Immunol."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"e587","DOI":"10.1016\/j.clgc.2017.10.019","article-title":"Intravesical Immunomodulatory Imiquimod Enhances Bacillus Calmette-Gu\u00e9rin Downregulation of Nonmuscle-invasive Bladder Cancer","volume":"16","author":"Camargo","year":"2018","journal-title":"Clin. Genitourin. Cancer"},{"key":"ref_70","first-page":"e1","article-title":"A phase 2 study of TMX-101, intravesical imiquimod, for the treatment of carcinoma in situ bladder cancer","volume":"35","author":"Donin","year":"2017","journal-title":"Urol. Oncol. Semin. Orig. Investig."},{"key":"ref_71","doi-asserted-by":"crossref","unstructured":"Rentsch, C.A., Thalmann, G.N., Lucca, I., Kwiatkowski, M., Wirth, G.J., Strebel, R.T., Engeler, D., Pedrazzini, A., H\u00fcttenbrink, C., and Schultze-Seemann, W. (2022). A Phase 1\/2 Single-arm Clinical Trial of Recombinant Bacillus Calmette-Gu\u00e9rin (BCG) VPM1002BC Immunotherapy in Non\u2013muscle-invasive Bladder Cancer Recurrence after Conventional BCG Therapy: SAKK 06\/14. Eur. Urol. Oncol., 1\u20138.","DOI":"10.1016\/j.euo.2021.12.006"},{"key":"ref_72","first-page":"1771","article-title":"Functions of EpCAM in physiological processes and diseases","volume":"42","author":"Huang","year":"2018","journal-title":"Int. J. Mol. Med."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"1712","DOI":"10.1016\/j.juro.2012.07.020","article-title":"A phase II study of oportuzumab monatox: An immunotoxin therapy for patients with noninvasive urothelial carcinoma in situ previously treated with bacillus Calmette-Gu\u00e9rin","volume":"188","author":"Kowalski","year":"2012","journal-title":"J. Urol."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1038\/s41585-020-00394-5","article-title":"The biology and rationale of targeting nectin-4 in urothelial carcinoma","volume":"18","author":"Heath","year":"2021","journal-title":"Nat. Rev. Urol."},{"key":"ref_75","first-page":"409","article-title":"Fibroblast growth factor receptor: A systematic review and meta-analysis of prognostic value and therapeutic options in patients with urothelial bladder carcinoma","volume":"39","author":"Margulis","year":"2021","journal-title":"Urol. Oncol. Semin. Orig. Investig."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"4526","DOI":"10.1200\/JCO.2016.34.15_suppl.4526","article-title":"Phase 2 trial of dovitinib in Bacillus Calmette-Guerin (BCG) refractory urothelial carcinoma (UC) with tumor FGFR3 mutations or over-expression: Hoosier Cancer Research Network GU12-157","volume":"34","author":"Hahn","year":"2016","journal-title":"J. Clin. Oncol."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.2174\/092986712799320709","article-title":"The Development of MetAP-2 Inhibitors in Cancer Treatment","volume":"19","author":"Yin","year":"2012","journal-title":"Curr. Med. Chem."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1200\/JCO.2017.35.6_suppl.303","article-title":"An oral methionine aminopeptidase II inhibitor for high-risk non-muscle invasive bladder cancer relapsed after intravesical therapies: Update of a phase II trial","volume":"35","author":"Ye","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"11541","DOI":"10.1007\/s13277-016-5083-1","article-title":"mTOR inhibitors in urinary bladder cancer","volume":"37","author":"Sousa","year":"2016","journal-title":"Tumor Biol."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.acuroe.2020.08.011","article-title":"Current treatments for BCG failure in non-muscle invasive bladder cancer (NMIBC)","volume":"45","year":"2021","journal-title":"Actas Urol\u00f3gicas Espa\u00f1olas"},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1016\/j.juro.2009.06.017","article-title":"Combined Thermo-Chemotherapy for Recurrent Bladder Cancer After Bacillus Calmette-Guerin","volume":"182","author":"Nativ","year":"2009","journal-title":"J. Urol."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"395","DOI":"10.3233\/BLC-180191","article-title":"Hyperthermic Intravesical Chemotherapy for BCG Unresponsive Non-Muscle Invasive Bladder Cancer Patients","volume":"4","author":"Hendricksen","year":"2018","journal-title":"Bladder Cancer"},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1007\/s00345-015-1595-3","article-title":"Efficacy and safety of a new device for intravesical thermochemotherapy in non-grade 3 BCG recurrent NMIBC: A phase I\u2013II study","volume":"34","author":"Soria","year":"2016","journal-title":"World J. Urol."},{"key":"ref_84","doi-asserted-by":"crossref","unstructured":"Racioppi, M., DI Gianfrancesco, L., Ragonese, M., Palermo, G., Sacco, E., and Bassi, P.F. (2018). ElectroMotive drug administration (EMDA) of Mitomycin C as first-line salvage therapy in high risk \u201cbCG failure\u201d non muscle invasive bladder cancer: 3 years follow-up outcomes. BMC Cancer, 18.","DOI":"10.1186\/s12885-018-5134-7"}],"container-title":["Cells"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2073-4409\/11\/3\/357\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T22:05:15Z","timestamp":1760133915000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2073-4409\/11\/3\/357"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1,21]]},"references-count":84,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2022,2]]}},"alternative-id":["cells11030357"],"URL":"https:\/\/doi.org\/10.3390\/cells11030357","relation":{},"ISSN":["2073-4409"],"issn-type":[{"value":"2073-4409","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,1,21]]}}}